血清 miR-146a 和 miR-223 作为脓毒症潜在的新型生物标志物。
Serum miR-146a and miR-223 as potential new biomarkers for sepsis.
机构信息
Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
出版信息
Biochem Biophys Res Commun. 2010 Mar 26;394(1):184-8. doi: 10.1016/j.bbrc.2010.02.145. Epub 2010 Feb 24.
OBJECTIVE
Current biomarkers cannot completely distinguish sepsis from systemic inflammatory response syndrome (SIRS) caused by other non-infectious diseases. Circulating microRNAs (miRNAs) are promising biomarkers for several diseases, but their correlation with sepsis is not totally clarified.
METHODS
Seven miRNAs related to inflammation or infection were included in the present study. Serum miRNA expression was investigated in 50 patients diagnosed with sepsis, 30 patients with SIRS and 20 healthy controls to evaluate the diagnostic and prognostic value. Expression levels of serum miRNAs were determined by quantitative PCR using the Qiagen miScript system. Serum CRP and IL-6 levels were determined by enzyme linked immunosorbent assay.
RESULTS
Serum miR-146a and miR-223 were significantly reduced in septic patients compared with SIRS patients and healthy controls. The areas under the receiver operating characteristic curve of miR-146a, miR-223 and IL-6 were 0.858, 0.804 and 0.785, respectively.
CONCLUSION
Serum miR-146a and miR-223 might serve as new biomarkers for sepsis with high specificity and sensitivity. (ClinicalTrials.gov number, NCT00862290.).
目的
目前的生物标志物不能完全区分感染性休克与由其他非传染性疾病引起的全身炎症反应综合征（SIRS）。循环 microRNAs（miRNAs）是几种疾病有前途的生物标志物，但它们与脓毒症的相关性尚未完全阐明。
方法
本研究纳入了 7 种与炎症或感染相关的 miRNA。通过定量 PCR 使用 Qiagen miScript 系统检测 50 例脓毒症患者、30 例 SIRS 患者和 20 例健康对照者血清 miRNA 的表达，以评估其诊断和预后价值。采用酶联免疫吸附试验检测血清 CRP 和 IL-6 水平。
结果
与 SIRS 患者和健康对照组相比，脓毒症患者血清 miR-146a 和 miR-223 水平显著降低。miR-146a、miR-223 和 IL-6 的受试者工作特征曲线下面积分别为 0.858、0.804 和 0.785。
结论
血清 miR-146a 和 miR-223 可能是脓毒症的新型生物标志物，具有较高的特异性和敏感性。（临床试验注册号：NCT00862290.）。
Zotero 插件